Amgen and Gilead Face Conflicting Valuation Signals

Recent analysis of Amgen Inc. and Gilead Sciences highlights how differing valuation approaches can produce sharply contrasting signals, even as both large biopharmaceutical stocks post strong share price performance over the past year.

Amgen’s stock last closed at $377.64, delivering returns of 15.3% year to date and about 24% over the past year. Shorter term moves have been relatively steady, with a 0.4% decline over seven days and a 0.5% gain over 30 days, keeping the share price close to its recent highs.

MarketBeat data show Amgen shares trading near a 52‑week range of $261.43 to $391.29, with a market capitalization of $203.57 billion. The stock trades on a price‑earnings ratio of 26.54, a PEG ratio of 3.72 and has a beta of 0.45, indicating lower volatility than the broader market.

Amgen’s latest reported quarter, for which results were released on February 3, showed earnings per share of $5.29, beating the $4.76 consensus estimate. Revenue came in at $9.87 billion, ahead of expectations of $9.46 billion and up 8.6% year on year, while net margin was 20.98% and return on equity was 148.37%.

The company has issued FY 2026 guidance of $21.60 to $23.00 in EPS, and analysts on average expect 20.62 EPS for the current fiscal year. Amgen also declared a quarterly dividend of $2.52 per share, payable June 5 to shareholders of record on May 15, implying an annualized $10.08 dividend and a 2.7% yield, with a payout ratio of 70.84%.

SevenBridge Financial Group LLC reduced its Amgen position by 24.1% in the third quarter, selling 2,689 shares and ending the period with 8,459 shares valued at $2.387 million. Several other institutions, including Evelyn Partners Investment Management, Howard Hughes Medical Institute, Cloud Capital Management, AXS Investments and Winnow Wealth, reported new but relatively small stakes.

Overall, hedge funds and other institutional investors hold 76.50% of Amgen’s stock. On the research side, recent actions include Erste Group Bank upgrading Amgen from "hold" to "buy," Wells Fargo raising its price target from $325 to $375 with an "equal weight" rating, and Mizuho lifting its target from $280 to $295 with an "outperform" view.

Sanford C. Bernstein downgraded the shares from "outperform" to "market perform" with a $335 price objective, while Guggenheim raised its target from $305 to $347 and kept a "neutral" stance. Overall, one analyst rates Amgen a Strong Buy, fourteen rate it Buy, thirteen Hold and two Sell, giving an average rating of "Hold" and a consensus price target of $354.

Simply Wall St’s valuation checklist scores Amgen 4 out of 6, indicating it screens as undervalued on four measures. A discounted cash flow model using last‑twelve‑month free cash flow of about $8.44 billion projects free cash flow rising to $16.11 billion by 2030 and extends assumptions to 2035.

Discounting those projected cash flows back to today yields an estimated intrinsic value of $658.78 per share, implying Amgen is about 42.7% undervalued versus the recent $377.64 price on this DCF view. A separate price‑earnings based analysis shows Amgen trading at 26.4 times earnings.

That multiple is above the broader biotechs industry average of 21.46 times but below a peer group average of 41.69 times. Simply Wall St’s proprietary "Fair Ratio" for Amgen is 28.86 times, and comparing this to the current 26.4 times suggests the shares also screen as undervalued on this earnings multiple metric.

Simply Wall St’s "Narratives" tool frames a range of fair values for Amgen based on different revenue and margin assumptions. A bullish case assigns a fair value of $432 per share, about 12.6% above the recent price, assuming 4.70% annual revenue growth supported by obesity and cardiovascular programs, a broad product base, AI‑supported R&D and capacity for further M&A while sustaining higher margins and free cash flow.

A cautious case estimates fair value at about $230.89 per share, roughly 63.6% below the recent share price, based on 5.37% annual revenue decline, pressure from patent expiries and competition, and the risk that new products do not fully offset erosion in legacy franchises amid pricing and cost headwinds.

Gilead Sciences has attracted renewed investor focus following a roughly 20% share price gain over three months and about 32% over the past year. Over 90 days the stock returned 18.5%, while one‑day and one‑month moves have been slightly negative, indicating strong but recently moderating momentum.

With annual revenue of about $29.4 billion and net income of around $8.5 billion, Gilead now trades near $146 per share, about 7% below the average analyst price target. Simply Wall St notes an estimated intrinsic value gap of roughly 47%, raising questions over how much future growth is already reflected in the price.

The most followed valuation narrative assigns Gilead a fair value of $132.57 per share, about 10.1% below the current price, and therefore characterizes the stock as overvalued on that basis. This scenario assumes an expanded pipeline in oncology, cell therapy and next‑generation HIV regimens, with multiple new product launches by 2030 and expectations for steadier growth, rising margins and a richer earnings multiple.

By contrast, a discounted cash flow analysis from the same source suggests a fair value of about $277.24 per share, or roughly 47% above the current $146 price, indicating undervaluation under that method. The divergence between the narrative‑based fair value and the DCF output underscores how different modeling assumptions can lead to opposing conclusions on Gilead’s valuation.